O'Steen et al. utilized pretargeted RIT (PRIT) system directed against the CD20 antigen on leukemic cells and observed tumor reduction with a beta‐emitter 90Y.16Very recently, the same group investigated targeting CD45 antigen on leukemic cells with the novel bispecific fusion proteins targeting CD45 and 90Y‐DOTA 34 and observed tumor reduction, confirming the potential of beta emitters in radioimmunotherapy of AML. This evidence concerns the gene PTPRC and acute myeloid leukemia.